These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12713826)

  • 21. Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors.
    Vacondio F; Mor M; Silva C; Zuliani V; Rivara M; Rivara S; Bordi F; Plazzi PV; Magnanini F; Bertoni S; Ballabeni V; Barocelli E; Carrupt PA; Testa B
    Eur J Pharm Sci; 2004 Sep; 23(1):89-98. PubMed ID: 15324926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ciproxifan and chemically related compounds are highly potent and selective histamine H3-receptor antagonists.
    Kathmann M; Schlicker E; Marr I; Werthwein S; Stark H; Schunack W
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):623-7. PubMed ID: 9879720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
    Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
    J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potencies of antagonists chemically related to iodoproxyfan at histamine H3 receptors in mouse brain cortex and guinea-pig ileum: evidence for H3 receptor heterogeneity?
    Schlicker E; Kathmann M; Bitschnau H; Marr I; Reidemeister S; Stark H; Schunack W
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):482-8. PubMed ID: 8740140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel carbamates as potent histamine H3 receptor antagonists with high in vitro and oral in vivo activity.
    Stark H; Purand K; Ligneau X; Rouleau A; Arrang JM; Garbarg M; Schwartz JC; Schunack W
    J Med Chem; 1996 Mar; 39(5):1157-63. PubMed ID: 8676353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists.
    Meier G; Apelt J; Reichert U; Grassmann S; Ligneau X; Elz S; Leurquin F; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Eur J Pharm Sci; 2001 Jun; 13(3):249-59. PubMed ID: 11384847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents.
    Petroianu G; Arafat K; Sasse BC; Stark H
    Pharmazie; 2006 Mar; 61(3):179-82. PubMed ID: 16599255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and histamine H3 receptor activity of 4-(n-alkyl)-1H-imidazoles and 4-(omega-phenylalkyl)-1H-imidazoles.
    De Esch IJ; Gaffar A; Menge WM; Timmerman H
    Bioorg Med Chem; 1999 Dec; 7(12):3003-9. PubMed ID: 10658607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
    Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel histamine H3-receptor antagonists with benzyl ether structure or related moieties: synthesis and structure-activity relationships.
    Hüls A; Purand K; Stark H; Reidemeister S; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Arch Pharm (Weinheim); 1996; 329(8-9):379-85. PubMed ID: 8915097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-[(1H-imidazol-4-yl) methyl] benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor.
    Aslanian R; Brown JE; Shih NY; wa Mutahi M; Green MJ; She S; Del Prado M; West R; Hey J
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2263-8. PubMed ID: 9873525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of the lipophilic group in carbamates having histamine H3-receptor antagonist activity.
    Kieć-Kononowicz K; Wiecek M; Sasse A; Ligneau X; Elz S; Ganellin CR; Schwartz JC; Stark H; Schunack W
    Pharmazie; 2000 May; 55(5):349-55. PubMed ID: 11828613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Search for novel leads for histamine H3-receptor antagonists: amine derivatives.
    Stark H; Ligneau X; Lipp R; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jun; 52(6):419-23. PubMed ID: 9260265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models.
    Tedford CE; Hoffmann M; Seyedi N; Maruyama R; Levi R; Yates SL; Ali SM; Phillips JG
    Eur J Pharmacol; 1998 Jun; 351(3):307-11. PubMed ID: 9721022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template.
    Aslanian R; Mutahi MW; Shih NY; McCormick KD; Piwinski JJ; Ting PC; Albanese MM; Berlin MY; Zhu X; Wong SC; Rosenblum SB; Jiang Y; West R; She S; Williams SM; Bryant M; Hey JA
    Bioorg Med Chem Lett; 2002 Mar; 12(6):937-41. PubMed ID: 11958998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piperidine variations in search for non-imidazole histamine H(3) receptor ligands.
    Łazewska D; Kuder K; Ligneau X; Schwartz JC; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem; 2008 Sep; 16(18):8729-36. PubMed ID: 18774720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. General construction pattern of histamine H3-receptor antagonists: change of a paradigm.
    Stark H; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Bioorg Med Chem Lett; 1998 Aug; 8(15):2011-6. PubMed ID: 9873477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in the rat brain histamine content following metoprine and other histamine-methyltransferase (HMT) inhibitors.
    Zawilska J; Nowak JZ
    Pol J Pharmacol Pharm; 1985; 37(6):821-30. PubMed ID: 3832018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.